Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases

Yasmin Alfallouji; Ashley Spencer; Eduardo Calonje; Conal M Perrett; Richard Watchorn; Catherine Borysiewicz; Tara Hodgkinson; Harpreet Wasan; Christopher B Bunker; Rachel U Sidwell

doi:10.1111/ced.15276

Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases

Clin Exp Dermatol. 2022 Oct;47(10):1857-1858. doi: 10.1111/ced.15276. Epub 2022 Jul 27.

Authors

Affiliations

¹ University College London Hospital NHS Trust, London, UK.
² Imperial College NHS Trust, London, UK.
³ Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁴ The Devonshire Clinic, London, UK.
⁵ West Hertfordshire Hospitals NHS Trust, London, UK.

PMID: 35633107
DOI: 10.1111/ced.15276

Abstract

Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer. BRAF inhibitors have been reported to be associated with new and changing melanocytic lesions, including eruptive naevi. We describe two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF-mutant metastatic colorectal cancer.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Carbamates
Colonic Neoplasms*
Exanthema*
Humans
Mutation
Nevus, Pigmented* / pathology
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics
Rectal Neoplasms*
Skin Neoplasms* / chemically induced
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology
Sulfonamides

Substances

Carbamates
Protein Kinase Inhibitors
Sulfonamides
encorafenib
Proto-Oncogene Proteins B-raf